Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) reported Q3 EPS of ($0.24), $0.02 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Acumen Pharmaceuticals, Inc. (ABOS) click here.